These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24836763)

  • 21. To target the untargetable: elucidation of synergy of APR-246 and azacitidine in
    Sallman DA
    Haematologica; 2020 Jun; 105(6):1470-1472. PubMed ID: 32482751
    [No Abstract]   [Full Text] [Related]  

  • 22. Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
    Maslah N; Rety S; Bonnamy M; Aguinaga L; Huynh T; Parietti V; Giraudier S; Fenaux P; Cassinat B
    Leukemia; 2024 Jul; 38(7):1630-1633. PubMed ID: 38777834
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
    Abáigar M; Ramos F; Benito R; Díez-Campelo M; Sánchez-del-Real J; Hermosín L; Rodríguez JN; Aguilar C; Recio I; Alonso JM; de las Heras N; Megido M; Fuertes M; del Cañizo MC; Hernández-Rivas JM
    Ann Hematol; 2013 Nov; 92(11):1543-52. PubMed ID: 23740492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
    Villela L; Anders V; Bolaños-Meade J
    Anticancer Drugs; 2010 Apr; 21(4):469. PubMed ID: 20216343
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment With Azacitidine in the Context of Palliative Care for a Patient With Acute Myeloid Leukemia Complicating Fanconi Anemia With Biallelic FANCD1/BRCA 2 Mutations.
    Berot A; Pluchart C
    J Pediatr Hematol Oncol; 2018 Apr; 40(3):247-248. PubMed ID: 29389832
    [No Abstract]   [Full Text] [Related]  

  • 26. Transplantation for MDS in the elderly: more evidence, or more bias?
    Cutler C
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1320-1. PubMed ID: 22750646
    [No Abstract]   [Full Text] [Related]  

  • 27. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
    Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
    Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
    Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
    Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
    [No Abstract]   [Full Text] [Related]  

  • 29. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
    Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
    Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
    Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
    Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
    [No Abstract]   [Full Text] [Related]  

  • 31. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
    Chang CK; Zhao YS; Xu F; Guo J; Zhang Z; He Q; Wu D; Wu LY; Su JY; Song LX; Xiao C; Li X
    Br J Haematol; 2017 Feb; 176(4):600-608. PubMed ID: 27984642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy.
    Kara A; Akın Belli A; Karakuş V; Dere Y; Kurtoğlu E
    Turk J Haematol; 2017 Jun; 34(2):192-193. PubMed ID: 28183685
    [No Abstract]   [Full Text] [Related]  

  • 34. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.
    Boasman K; Simmonds MJ; Graham C; Saunthararajah Y; Rinaldi CR
    Ann Hematol; 2019 Jun; 98(6):1529-1531. PubMed ID: 30721335
    [No Abstract]   [Full Text] [Related]  

  • 37. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
    Ettou S; Audureau E; Humbrecht C; Benet B; Jammes H; Clozel T; Bardet V; Lacombe C; Dreyfus F; Mayeux P; Solary E; Fontenay M
    Leukemia; 2012 Oct; 26(10):2297-9. PubMed ID: 22743624
    [No Abstract]   [Full Text] [Related]  

  • 38. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.
    Sockel K; Wermke M; Radke J; Kiani A; Schaich M; Bornhäuser M; Ehninger G; Thiede C; Platzbecker U
    Haematologica; 2011 Oct; 96(10):1568-70. PubMed ID: 21750085
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.